| Autor: |
Pranzatelli MR; Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA.; Department of Pediatrics, Southern Illinois University School of Medicine, Springfield, Illinois, USA., Travelstead AL; Department of Medical Microbiology and Immunology, Southern Illinois University School of Medicine, Springfield, Illinois, USA., Tate ED; Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA., Allison TJ; Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA., Verhulst SJ; Statistics and Research Consulting, Southern Illinois University School of Medicine, Springfield, Illinois, USA. |
| Abstrakt: |
Lack of a biomarker of disease activity has hindered the therapy of childhood opsoclonus-myoclonus syndrome (OMS), which is purported to be mediated humorally. To determine if the cerebrospinal fluid (CSF) B lymphocyte, which may traffic into the central nervous system (CNS) to produce antibody locally, is one such biomarker, B lymphocytes were immunophenotyped in the CSF and blood of 56 children with OMS and 26 pediatric controls by dual-laser flow cytometry. Neurological severity was rated blindly from videotapes using a validated 12-item motor evaluation scale. Children with OMS manifested a 4- to 7-fold higher percentage of total B-cells in CSF (P < 0.0001), including CD5(+) (P = 0.001) and CD5(-) (P = 0.0004) B-cell subsets, compared with controls, in whom the percentages were negligible and unchanging with age. CSF expansion of both B-cell subsets increased with disease severity and decreased with disease duration (P (Copyright 2004 Movement Disorder Society) |
Plný text